Adam W. Nowlan
Expertise in
26
conditions

Dr. Adam W. Nowlan

Radiation Oncology
200 Bill Hasty Blvd, 
Jasper, GA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
26
conditions
200 Bill Hasty Blvd, 
Jasper, GA 

Overview

Adam Nowlan, MD is a board-certified radiation oncologist, currently practicing and serving as Medical Director of the radiation oncology department at Piedmont Hospital in Atlanta, GA.Dr. Nowlan is very active in clinical research activities. He previously chaired the Piedmont Healthcare Institutional Review Board and is an active member of the Piedmont Hospital Oncology Scientific Review Committee.Dr. Nowlan has been named to sit on the recently convened Piedmont Healthcare Oncology Clinical Governance Committee, responsible for executive guidance of system initiatives.Dr. Nowlan serves as the Piedmont Healthcare principal investigator for the Radiation Therapy Oncology Group clinical trials that are open at Piedmont Hospital locations in Buckhead, Atlanta and Fayette.Dr. Nowlan is a member of the clinical trials team at the recently launched Piedmont Hospital Brain Tumor Center.Throughout his medical experience, Dr. Nowlan's work has appeared in several publications, and he has engaged in research projects and presentations on a wide variety of relevant radiation oncology subjects.In his spare time, Dr. Nowlan enjoys skiing, watching roller derby and spending time with his wife and family.

Dr. Nowlan is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Astrocytoma, Lung Cancer, Pleuropulmonary Blastoma, and Awake Craniotomy.

Dr. Nowlan is board certified in American Board Of Radiology. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 25 clinical trials. Dr. Nowlan is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in GA

Board Certifications

American Board Of Radiology

Hospital Affiliations

Piedmont Mountainside Hospital Inc
Piedmont Cartersville Medical Center
Piedmont Hospital, Inc
Wellstar Kennestone Regional Medical Center
Northside Hospital

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Piedmont Physicians Radiation Oncology Mountainside
200 Bill Hasty Blvd, Jasper, GA 30143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 2
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: July 13, 2026
Intervention Type: Radiation
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

3 Total Publications

Chordoid glioma of the third ventricle: report of a rapidly progressive case.
Chordoid glioma of the third ventricle: report of a rapidly progressive case.
Journal: Journal of neuro-oncology
Published: October 10, 2016
Similar Doctors
Expertise in
30
conditions
Dr. Hui-kuo G. Shu
Radiation Oncology
Expertise in
30
conditions
Dr. Hui-kuo G. Shu
Radiation Oncology
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (46.4 miles away)
404-778-3473
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Hui-kuo Shu is a Radiation Oncologist practicing medicine in Atlanta, Georgia. Dr. Shu is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, and Glioma. Dr. Shu is board certified in American Board Of Radiology, 1999. Dr. Shu is currently accepting new patients.

Expertise in
6
conditions
Dr. Ashesh B. Jani
Radiation Oncology
Expertise in
6
conditions
Dr. Ashesh B. Jani
Radiation Oncology
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (46.4 miles away)
404-778-3473
Languages Spoken:
English, German, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ashesh Jani is a Radiation Oncologist practicing medicine in Atlanta, Georgia. Dr. Jani is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Muscle Invasive Bladder Cancer, Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Prostatectomy. Dr. Jani is board certified in American Board Of Radiology, 2001. Dr. Jani is currently accepting new patients.

Expertise in
40
conditions
Dr. Mark P. Mclaughlin
Radiation Oncology
Expertise in
40
conditions
Dr. Mark P. Mclaughlin
Radiation Oncology
Referral may be required

North Georgia Radiation Therapy

320 Kennestone Hospital Blvd Ste LL1, 
Marietta, GA 
 (37.4 miles away)
770-793-7500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Mclaughlin is a Radiation Oncologist practicing medicine in Marietta, Georgia. Dr. Mclaughlin is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Metastatic Brain Tumor. Dr. Mclaughlin is currently accepting new patients.

Frequently Asked Questions about Dr. Adam W. Nowlan

How do I make an appointment with Dr. Adam W. Nowlan?

You can book an appointment with Dr. Adam W. Nowlan by calling their office at 706-299-2070. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Adam W. Nowlan a top-rated expert for Posterior Fossa Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Adam W. Nowlan is classified as an Distinguished expert for Posterior Fossa Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Adam W. Nowlan specialize in?

While Dr. Adam W. Nowlan is a Radiation Oncology, they have specific expertise in Posterior Fossa Tumor, Astrocytoma, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Adam W. Nowlan participate in research or clinical trials?

Yes. Dr. Adam W. Nowlan has published 3 articles and abstracts on conditions like Posterior Fossa Tumor. You can view a list of Dr. Adam W. Nowlan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Adam W. Nowlan accept my insurance?

Dr. Adam W. Nowlan accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 706-299-2070 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nowlan's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 73 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile